German biotechnology company CureVac said on November 18 that clinical trials for its second-generation COVID-19 vaccine will begin in the next few months.
Highlights
- CureVac to begin clinical trials of its second-generation COVID-19 vaccine
- This vaccine uses improved mRNA vaccine technology
Earlier, the company published data which showed that the next-generation shot C....
Tags : Development, Efficacy, CureVac, CVnCoV, mRNA Vaccine,
comments (0)